ClinicalTrials.gg
CompletedNCT01601821Updated Dec 12, 2018Results posted

Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids

A Phase 4 interventional study of CsA+Rapamune+CS and CsA+MMF+CS in Inflammation, sponsored by Pfizer. Completed at 4 sites in Iran, Islamic Republic of. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-12-12.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Inflammation with a site in Iran, Islamic Republic of — 1 open to participants now, 3 under way, none of them phase 3. Inflammation · Iran, Islamic Republic of.

Enrollment
Largest of 22
245 · median 80
Started
2006
the only one that year
Phase 4
4 of 24
none open now
Registered
5th of 24
by date

Among the 24 studies in Inflammation with a site in Iran, Islamic Republic of, this one has the largest enrollment of the 22 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 4, and was the 5th registered.

Inflammation

3,541 studies on the registry are indexed under Inflammation; 646 are open to participants now.

Browse Inflammation studies →

Open to participants now

1 of the 24 studies in Inflammation with a site in Iran, Islamic Republic of is open now. Recruiting first, the newest first:

A study can be open while its sites in Iran, Islamic Republic of have not opened yet or have stopped. Only those recruiting at a site in Iran, Islamic Republic of →

Who these studies take

Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Inflammation with a site in Iran, Islamic Republic of, or all of them as a file.
02

Study summary

To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with the introduction of MMF in de novo renal allograft recipients.

03

Conditions studied

  • Inflammation

Browse trials for

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 13 years and weight 40 kg
  • End-stage renal disease, with patients receiving a primary or secondary renal allograft from a living-unrelated donor, or from a living-related donor.
  • Women who are of must have a negative pregnancy test before enrollment in the study and agree to use a medically acceptable method of throughout the treatment period and for 3 months following discontinuation from the study.
  • Total white blood cell count 4.0 x 109/L (4,000/mmP3P), count 100 x 10P9P/L(100,000/mmP3P), fasting triglycerides ≤ 4.6 mmol/L (400 mg/dL), fasting cholesterol ≤ 7.8 mmol/L (300 mg/dL). If it is not possible to obtain fasting triglycerides and cholesterol before surgery, historical values (within 1 year) may be used.
  • Signed and dated (parent or legal guardian must provide consent for patients \<18 years of age). An assent form will be signed by patients \< 18 years of age enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  • Evidence of active systemic or localized major infection at the time of initial Sirolimus administration.
  • Cadaveric donors
  • History of within 5 years before enrollment into the study (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin)
  • Use of any drug other than specified in the protocol during the 4 weeks before enrolling in the study.
  • Use of planned antibody induction therapy at the time of transplantation.
  • Active gastrointestinal disorder that may interfere with drug absorption.
  • Known to Sirolimus, MMF or Cyclosporine or its derivatives.
  • Multiple organ transplants (2 or more organ transplant e.g. Kidney and Pancreas).
  • Patient with high risk of rejection (eg. Patients with a PRA >50%, black patients and patients with 2nd transplant who lost their first graft within the first 6 months).
  • Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during pre-study screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
245 participants (actual)

Study arms

  • Active comparator
    Arm A (CsA+Rapamune+CS)

    Drug: CsA+Rapamune+CS

  • Experimental
    Arm B (CsA+MMF+CS)

    Drug: CsA+MMF+CS

Interventions

  • DrugCsA+Rapamune+CS

    Drug pages: Cyclosporine · Sirolimus

    Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months

  • DrugCsA+MMF+CS

    Drug pages: Cyclosporine · Mycophenolic Acid

    The control arm is the standard local practice (official protocol) in Iran: Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.

06

What researchers measure

Primary outcomes

  1. Incidence of Efficacy Failure

    Efficacy failure was defined as first occurrence of either biopsy confirmed acute rejection, graft loss or death within 12 months of post-transplantation. Percentage of participants with efficacy failure was reported.

    Time frame: Baseline up to Month 12

Secondary outcomes

  1. Serum Creatinine Level

    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 milligram per deciliter (mg/dL) for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.

    Time frame: Month 3, 6, 12

  2. Creatinine Clearance

    Creatinine clearance (CCr) is a measure of kidney function. CCr is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Normal values for healthy, young males are in the range of 100-135 millimeters per minute (mL/min) and for females, 90-125 mL/min. Creatinine clearance decreases with age. A low creatinine clearance rate indicates poor kidney function.

    Time frame: Month 3, 6, 12

  3. Glomerular Filtration Rate (GFR) by Nankivell Method

    GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR was calculated using the Nankivell formula. GFR by Nankivell equation= (6.7 per serum creatinine) plus (0.25\*body weight) minus (0.5\*serum urea) minus (100 per height square) plus (35 for male or 25 for female). A normal GFR is greater than (\>)90 mL/min per 1.73 m\^2 \[mL/min/1.73 m\^2\], although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (\<)15 mL/min/1.73 m\^2 indicated kidney failure.

    Time frame: Month 3, 6, 12

  4. Incidence of Biopsy-Confirmed Acute Rejection

    Diagnosis of acute rejection was made via kidney biopsy using Banff criteria. Percentage of participants with biopsy-confirmed acute rejection was reported.

    Time frame: Baseline up to Month 6

  5. Histologic Grade of First Acute Rejection

    Diagnosis of acute rejection was made via kidney biopsy. Categorization of biopsies with suspected acute rejection was based on histological findings using updated 1997 Banff criteria. Grade 1A: cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (5-10 cells/tubular cross section), Grade 1B: with severe tubulitis (\>10 cells/tubular cross section), Grade 2A: mild-moderate intimal arteritis, Grade 2B: severe intimal arteritis and Grade 3: transmural arterits and/or fibrinoid necrosis. Data is reported as percentage of participants.

    Time frame: Baseline up to Month 12

  6. Percentage of Participants Who Survived

    Survival defined as participants living with or without a functioning graft.

    Time frame: Month 12

  7. Percentage of Participants With Graft Survival

    Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

    Time frame: Month 12

  8. Incidence of Presumptive or Documented Infection

    Presumptive or documented infection during the 12 months after transplantation; was confirmed by culture, biopsy, or serology and reported. Percentage of participants with presumptive or documented infection was reported.

    Time frame: Baseline up to Month 12

  9. Incidence of Histologically Confirmed Lymphoproliferative Disease

    Lymphoproliferative disorder represents an abnormal proliferation of B cells in response to either primary or reactivated infection with Epstein-Barr virus. Percentage of participants with histologically confirmed lymphoproliferative disease was reported.

    Time frame: Baseline up to Month 12

  10. Percentage of Participants With Efficacy Failure or Premature Elimination

    Efficacy failure was defined as the first occurrence of acute rejection, graft loss, or death. Premature elimination was defined as elimination from the study for any other reason.

    Time frame: Month 12

  11. Incidence of Anemia

    Diagnostic criterion for anemia was based on the laboratory results; in men: hemoglobin (Hb) \<14 gram per deciliter (g/dL), hematocrit (Hct) \<42%, or red blood cells (RBCs) \<4.5 million/liter (million/L); for women: Hb \<12 g/dL, Hct \<37%, or RBC \< 4 million/L. Percentage of participants with anaemia was reported.

    Time frame: Baseline up to Month 12

  12. Number of Participants Who Discontinued

    Number of participants who discontinued the study treatment due to any reason is reported.

    Time frame: Month 12

07

Results

Posted Jun 19, 2013

Participant flow

Participant flow — Overall Study
MilestoneCsA+Rapamune+CSCsA+MMF+CS
Started125120
Completed9691
Not completed2929
Withdrew: Death25
Withdrew: Protocol violation22
Withdrew: Lost to follow-up614
Withdrew: Withdrawal by subject10
Withdrew: Graft loss66
Withdrew: Study events71
Withdrew: Other51

Outcome measures

PrimaryIncidence of Efficacy Failure

Efficacy failure was defined as first occurrence of either biopsy confirmed acute rejection, graft loss or death within 12 months of post-transplantation. Percentage of participants with efficacy failure was reported.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Incidence of Efficacy Failure
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Incidence of Efficacy Failure11.413.5
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Chi-squared · p = 0.341 · Percent difference: -2.0 · 90% CI -5.5 to 1.5
SecondarySerum Creatinine Level

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 milligram per deciliter (mg/dL) for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.

Time frame:
Month 3, 6, 12
Reported as:
Mean · mg/dL
Serum Creatinine Level
mg/dLCsA+Rapamune+CSCsA+MMF+CS
Month 3 (n=102, 94)1.4 ± 0.41.4 ± 0.4
Month 6 (n=101, 92)1.2 ± 0.31.3 ± 0.4
Month 12 (n=98, 91)1.2 ± 0.31.3 ± 0.3
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.870 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.381 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.096 (Statistical testing was based on 5% significance level.)
SecondaryCreatinine Clearance

Creatinine clearance (CCr) is a measure of kidney function. CCr is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Normal values for healthy, young males are in the range of 100-135 millimeters per minute (mL/min) and for females, 90-125 mL/min. Creatinine clearance decreases with age. A low creatinine clearance rate indicates poor kidney function.

Time frame:
Month 3, 6, 12
Reported as:
Mean · mL/min
Creatinine Clearance
mL/minCsA+Rapamune+CSCsA+MMF+CS
Month 3 (n=102, 94)64.0 ± 19.963.9 ± 16.0
Month 6 (n=101, 92)72.8 ± 19.371.6 ± 18.3
Month 12 (n=98, 91)76.4 ± 22.774.0 ± 28.6
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.979 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.660 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.518 (Statistical testing was based on 5% significance level.)
SecondaryGlomerular Filtration Rate (GFR) by Nankivell Method

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR was calculated using the Nankivell formula. GFR by Nankivell equation= (6.7 per serum creatinine) plus (0.25\*body weight) minus (0.5\*serum urea) minus (100 per height square) plus (35 for male or 25 for female). A normal GFR is greater than (\>)90 mL/min per 1.73 m\^2 \[mL/min/1.73 m\^2\], although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (\<)15 mL/min/1.73 m\^2 indicated kidney failure.

Time frame:
Month 3, 6, 12
Reported as:
Mean · mL/min/1.73 m^2
Glomerular Filtration Rate (GFR) by Nankivell Method
mL/min/1.73 m^2CsA+Rapamune+CSCsA+MMF+CS
Month 3 (n=102, 94)59.5 ± 20.458.8 ± 15.2
Month 6 (n=101, 92)65.2 ± 16.064.3 ± 19.5
Month 12 (n=98, 91)67.4 ± 17.567.5 ± 46.5
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.786 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.738 (Statistical testing was based on 5% significance level.)
  • CsA+Rapamune+CS vs CsA+MMF+CS · ANOVA · p = 0.977 (Statistical testing was based on 5% significance level.)
SecondaryIncidence of Biopsy-Confirmed Acute Rejection

Diagnosis of acute rejection was made via kidney biopsy using Banff criteria. Percentage of participants with biopsy-confirmed acute rejection was reported.

Time frame:
Baseline up to Month 6
Reported as:
Number · percentage of participants
Incidence of Biopsy-Confirmed Acute Rejection
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Incidence of Biopsy-Confirmed Acute Rejection4.03.2
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Fisher Exact · p = 0.999 (Statistical testing was based on 5% significance level.)
SecondaryHistologic Grade of First Acute Rejection

Diagnosis of acute rejection was made via kidney biopsy. Categorization of biopsies with suspected acute rejection was based on histological findings using updated 1997 Banff criteria. Grade 1A: cases with significant interstitial infiltration (\>25% of parenchyma affected) and foci of moderate tubulitis (5-10 cells/tubular cross section), Grade 1B: with severe tubulitis (\>10 cells/tubular cross section), Grade 2A: mild-moderate intimal arteritis, Grade 2B: severe intimal arteritis and Grade 3: transmural arterits and/or fibrinoid necrosis. Data is reported as percentage of participants.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Histologic Grade of First Acute Rejection
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
1A100.066.7
1B0.033.3
SecondaryPercentage of Participants Who Survived

Survival defined as participants living with or without a functioning graft.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Survived
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Percentage of Participants Who Survived98.094.8
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Fisher Exact · p = 0.276 (Statistical testing was based on 5% significance level.)
SecondaryPercentage of Participants With Graft Survival

Graft survival defined as those participants who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Graft Survival
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Percentage of Participants With Graft Survival94.193.8
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Fisher Exact · p = 0.999 (Statistical testing was based on 5% significance level.)
SecondaryIncidence of Presumptive or Documented Infection

Presumptive or documented infection during the 12 months after transplantation; was confirmed by culture, biopsy, or serology and reported. Percentage of participants with presumptive or documented infection was reported.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Incidence of Presumptive or Documented Infection
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Incidence of Presumptive or Documented Infection20.318.6
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Chi-squared · p = 0.868 (Statistical testing was based on 5% significance level.)
SecondaryIncidence of Histologically Confirmed Lymphoproliferative Disease

Lymphoproliferative disorder represents an abnormal proliferation of B cells in response to either primary or reactivated infection with Epstein-Barr virus. Percentage of participants with histologically confirmed lymphoproliferative disease was reported.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Incidence of Histologically Confirmed Lymphoproliferative Disease
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Incidence of Histologically Confirmed Lymphoproliferative Disease1.00.0
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Fisher Exact · p = 0.999 (Statistical testing was based on 5% significance level.)
SecondaryPercentage of Participants With Efficacy Failure or Premature Elimination

Efficacy failure was defined as the first occurrence of acute rejection, graft loss, or death. Premature elimination was defined as elimination from the study for any other reason.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Efficacy Failure or Premature Elimination
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Percentage of Participants With Efficacy Failure or Premature Elimination22.022.9
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Chi-squared · p = 0.985 (Statistical testing was based on 5% significance level.)
SecondaryIncidence of Anemia

Diagnostic criterion for anemia was based on the laboratory results; in men: hemoglobin (Hb) \<14 gram per deciliter (g/dL), hematocrit (Hct) \<42%, or red blood cells (RBCs) \<4.5 million/liter (million/L); for women: Hb \<12 g/dL, Hct \<37%, or RBC \< 4 million/L. Percentage of participants with anaemia was reported.

Time frame:
Baseline up to Month 12
Reported as:
Number · percentage of participants
Incidence of Anemia
percentage of participantsCsA+Rapamune+CSCsA+MMF+CS
Incidence of Anemia94.398.3
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Fisher Exact · p = 0.172 (Statistical testing was based on 5% significance level.)
SecondaryNumber of Participants Who Discontinued

Number of participants who discontinued the study treatment due to any reason is reported.

Time frame:
Month 12
Reported as:
Number · participants
Number of Participants Who Discontinued
participantsCsA+Rapamune+CSCsA+MMF+CS
Number of Participants Who Discontinued2929
Statistical analysis
  • CsA+Rapamune+CS vs CsA+MMF+CS · Chi-squared · p = 0.978 (Statistical testing was based on 5% significance level.)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CsA+Rapamune+CS—56/125 (44.8%)67/125 (53.6%)
CsA+MMF+CS—44/120 (36.7%)44/120 (36.7%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventCsA+Rapamune+CSCsA+MMF+CS
Blood creatinine increasedInvestigations17/1255/120
Transplant rejectionImmune system disorders13/12510/120
Urinary tract infectionInfections and infestations8/1253/120
Therapeutic agent toxicityInjury, poisoning and procedural complications6/1254/120
Cytomegalovirus infectionInfections and infestations1/1255/120
Cytomegalovirus test positivInvestigations1/1254/120
LeukopeniaBlood and lymphatic system disorders4/1251/120
ThrombocytopeniaBlood and lymphatic system disorders4/1251/120
GastroenteritisGastrointestinal disorders4/1251/120
Wound infectionInfections and infestations4/1251/120
Most frequent other events
Showing 10 of 56
Most frequent other events
EventCsA+Rapamune+CSCsA+MMF+CS
Liver function test abnormalInvestigations21/1258/120
Blood triglycerides increasedInvestigations15/1255/120
Blood cholesterol increasedInvestigations11/1253/120
ThrombocytopeniaBlood and lymphatic system disorders7/1250/120
Alanine aminotransferase increasedInvestigations7/1254/120
Blood creatinine increasedInvestigations4/1256/120
Haemoglobin decreasedInvestigations6/1256/120
Blood glucose increasedInvestigations6/1255/120
Urinary tract infectionInfections and infestations4/1255/120
LeukopeniaBlood and lymphatic system disorders5/1253/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)CsA+Rapamune+CSCsA+MMF+CSTotal
Mean38.2 ± 13.441.6 ± 15.139.9 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)CsA+Rapamune+CSCsA+MMF+CSTotal
Female474592
Male7875153
08

Study locations

4 sites
  • Labbafinejad Hospital
    Tehran, Iran, Islamic Republic of
  • Modarres Hospital
    Tehran, Iran, Islamic Republic of
  • Shariati Hospital
    Tehran, Iran, Islamic Republic of
  • Taleqani Hospital
    Tehran, Iran, Islamic Republic of
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 18, 2012
Start
Apr 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Jun 19, 2013
Last update
Dec 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01601821
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 18, 2012
Start date
Apr 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Jun 19, 2013
Last update
Dec 12, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Mycophenolic Acid

Start the discussion